Galactoside-binding-protein useful in the diagnosis and inhibition of of metastasis
US5801002A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Nov 22, 1995 |
| Grant date | Sep 1, 1998 |
| Priority date | — |
| Expiry date | Nov 22, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/827
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed are novel polypeptides possessing part or all of the amino acid sequence or primary structural conformation and one or more of the biological properties of certain galactoside-binding-proteins with apparent molecular weights of 34,000 and 31,000. Genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequences of amino acid residues of L-34-gal-lectin and L-31-gal-lectin are incorporated into vectors used to transform a host cell in culture. Also provided are antibodies against L-34-gal-lectin and L-31-gal-lectin and a method for inhibiting mammalian cell metastasis by treating mammalian cells in a living host with antibodies against L-34-gal-lectin or L-31-gal-lectin. A method of determining the metastatic potential of mammalian cells is also provided by which cells in vitro are contacted with antibodies against L-34-gal-lectin or L-31-gal-lectin which are labeled with a detectable probe. An elevated level of expression of L-34-gal-lectin or L-31-gal-lectin is indicative of metastatic potential.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.